<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405704</url>
  </required_header>
  <id_info>
    <org_study_id>DK074059 (IND)</org_study_id>
    <secondary_id>U01DK074059</secondary_id>
    <nct_id>NCT00405704</nct_id>
  </id_info>
  <brief_title>Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)</brief_title>
  <acronym>RIVUR</acronym>
  <official_title>Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this 2-year, multisite, randomized, placebo-controlled trial involving 607 children with
      vesicoureteral reflux that was diagnosed after a first or second febrile or symptomatic
      urinary tract infecton, we evaluated the efficacy of Trimethoprim-Sulfamethoxazole (TMP-SMZ)
      prophylaxis in preventing recurrences (primary outcome). Secondary outcomes were renal
      scarring, treatment failure (a composite of recurrences and scarring), and antimicrobial
      resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter, randomized, double-blind, placebo-controlled trial was designed to
      determine whether daily antimicrobial prophylaxis is superior to placebo in preventing
      recurrence of urinary tract infection (UTI) in children with vesicoureteral reflux (VUR).
      Eligibility criteria are described elsewhere. Patients were randomly assigned to treatment
      for 2 years with daily antimicrobial prophylaxis (trimethoprim-sulfamethoxazole) or placebo.
      The study was designed to recruit 600 children (approximately 300 in each treatment group).
      The protocol encouraged prompt evaluation of children with UTI symptoms and early therapy of
      culture-proven UTIs. It was expected that approximately 10% of children will have to
      discontinue study medication due to allergic reactions. Assuming a 20% placebo event rate and
      10% non-compliance rate, the study has 83% power to detect an absolute 10% event rate in the
      antimicrobial prophylaxis group. If the placebo event rate is instead 25%, power is 97% to
      detect an absolute 10% event rate in the treated group, even if non-compliance is as high as
      15%. The primary analysis is intention-to-treat with missing outcome data analyzed as UTI.

      In addition to collecting follow-up data on urinary tract infections, renal scarring and
      antimicrobial resistance, quality of life, compliance, safety parameters, utilization of
      health resources, and change in VUR were assessed periodically throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent Febrile or Symptomatic Urinary Tract Infection During 2-year Follow-up</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Outcome Renal Scarring</measure>
    <time_frame>2 years</time_frame>
    <description>Renal scarring was defined as a decreased uptake of tracer that was associated with loss of contours or the presence of cortical thinning. Outcome dimercaptosuccinic acid (DMSA) scan was performed at 2 years after enrollment or 3-4 months after the child had met treatment failure criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Renal Scarring on Outcome Scan</measure>
    <time_frame>2 years</time_frame>
    <description>Severe renal scarring was defined as scarring in more than 4 of 12 segments in at least one kidney or global atrophy characterized by diffusely scarred and shrunken kidney. Outcome DMSA scan performed at 2 years after enrollment or 3-4 months after the child had met treatment failure criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Renal Scarring on Outcome Scan</measure>
    <time_frame>2 years</time_frame>
    <description>New renal scarring was defined as scarring on the outcome renal scan with technetium -99m-labeled dimercaptosuccinic acid that was not present at baseline. Outcome DMSA scan performed at 2 years after enrollment or 3-4 months after the child had met treatment failure criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Failure Composite</measure>
    <time_frame>2 years</time_frame>
    <description>Treatment failure was defined as the occurrence of two febrile urinary tract infections (UTIs), one febrile UTI and three symptomatic UTIs, four symptomatic UTIs, or new or worsening renal scarring on an interim scan (e.g,, the 12-month visit); renal scans from the 2-year visit are NOT considered in the treatment failure criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of E.Coli Resistant to Trimethoprim-Sulfamethoxazole (TMP-SMZ) (Based on Rectal Swab)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Febrile or Symptomatic UTI With Resistant E. Coli</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Febrile or Symptomatic UTI With Any Resistant Pathogen</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">607</enrollment>
  <condition>Vesicoureteral Reflux</condition>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Trimethoprim-Sulfamethoxazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cherry-flavored liquid suspension matched to active comparator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim-Sulfamethoxazole</intervention_name>
    <description>Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.</description>
    <arm_group_label>Trimethoprim-Sulfamethoxazole</arm_group_label>
    <other_name>Sulfatrim</other_name>
    <other_name>Bactrim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Cherry flavored liquid suspension matched to active comparator.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at randomization: at least 2 months, but less than 6 years of age. Note that
             children as young as 1 month were screened for the study.

          -  Diagnosed first or second febrile or symptomatic UTI within 112 days prior to
             randomization

          -  Presence of Grade I- IV VUR based on radiographic voiding cystourethrogram (VCUG)
             performed within 112 days of diagnosis of index UTI.

          -  Appropriately treated index febrile or symptomatic UTI

        Exclusion Criteria:

          -  Index UTI diagnosis more than 112 days prior to randomization

          -  History of more than two UTIs prior to randomization

          -  For patients less than 6 months of age at randomization, gestational age less than 34
             weeks

          -  Co-morbid urologic anomalies

          -  Hydronephrosis, SFU Grade 4

          -  Ureterocele

          -  Urethral valve

          -  Solitary kidney

          -  Profoundly decreased renal size unilaterally on ultrasound (based on 2 standard
             deviations below the mean for age and length) performed within 112 days after
             diagnosis of index UTI

          -  Multicystic dysplastic kidney

          -  Neurogenic bladder

          -  Pelvic kidney or fused kidney

          -  Known sulfa allergy, inadequate renal or hepatic function, Glucose-6-phosphate
             dehydrogenase deficiency or other conditions that are contraindications for use of
             TMP-SMZ

          -  History of other renal injury/disease

          -  Unable to complete the study protocol

          -  Congenital or acquired immunodeficiency

          -  Underlying anomalies or chronic diseases that could potentially interfere with
             response to therapy such as chronic gastrointestinal conditions (i.e., malabsorption,
             inflammatory bowel disease), liver or kidney failure, or malignancy.

          -  Complex cardiac disease as defined in the Manual of Procedures.

          -  Any known syndromes associated with VUR or bladder dysfunction

          -  Index UTI not successfully treated

          -  Unlikely to complete follow-up

          -  Family history of anaphylactic reaction to sulfa medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>71 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sahar Fathallah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama, Birmingham, AL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myra A Carpenter, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of NC at Chapel Hill, Chapel Hill, NC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Caleb P. Nelson, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Boston, Boston, MA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eileen Brewer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Children's Hospital, Houston, TX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saul P Greenfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women and Children's Hospital of Buffalo, Buffalo, NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alejandro Hoberman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Pittsburgh, Pittsburgh, PA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ron Keren, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia, Philadelphia, PA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bradley P Kropp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma, Oklahoma City, OK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ranjiv Mathews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tej K Mattoo, MD,DCH, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University School of Medicine, Detroit, MI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H. Gil Rushton, MD, FAAP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Ann Queen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy Hospital Kansas City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Russell W Chesney, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Le Bonheur Children's Medical Center, Memphis, TN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven J Skoog, MD FACS,FAAP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health &amp; Science University, Portland, OR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amy Renwick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alfred I. duPont Hospital for Children, Wilmington, DE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Earl Y. Cheng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, IL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Milan Nadkarni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Baptist Medical Center, Winston-Salem, NC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Caleb P Nelson, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Boston, Boston, MA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William R DeFoor, Jr, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinnati Children's Hospital, Cincinnati, OH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan McMahon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akron Children's Hospital, Akron, OH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ross Decter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State Hershey Medical Center, Hershey, PA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharon M Bartosh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred I. duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Children's Hospital of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Children's Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://www.rivur.net</url>
    <description>RIVUR trial web site</description>
  </link>
  <reference>
    <citation>Ziessman HA, Majd M. Importance of methodology on (99m)technetium dimercapto-succinic acid scintigraphic image quality: imaging pilot study for RIVUR (Randomized Intervention for Children With Vesicoureteral Reflux) multicenter investigation. J Urol. 2009 Jul;182(1):272-9. doi: 10.1016/j.juro.2009.02.144. Epub 2009 May 17.</citation>
    <PMID>19450818</PMID>
  </reference>
  <reference>
    <citation>Mathews R, Carpenter M, Chesney R, Hoberman A, Keren R, Mattoo T, Moxey-Mims M, Nyberg L, Greenfield S. Controversies in the management of vesicoureteral reflux: the rationale for the RIVUR study. J Pediatr Urol. 2009 Oct;5(5):336-41. doi: 10.1016/j.jpurol.2009.05.010. Epub 2009 Jul 1. Review.</citation>
    <PMID>19570724</PMID>
  </reference>
  <reference>
    <citation>Keren R, Carpenter MA, Hoberman A, Shaikh N, Matoo TK, Chesney RW, Matthews R, Gerson AC, Greenfield SP, Fivush B, McLurie GA, Rushton HG, Canning D, Nelson CP, Greenbaum L, Bukowski T, Primack W, Sutherland R, Hosking J, Stewart D, Elder J, Moxey-Mims M, Nyberg L. Rationale and design issues of the Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) study. Pediatrics. 2008 Dec;122 Suppl 5:S240-50. doi: 10.1542/peds.2008-1285d.</citation>
    <PMID>19018048</PMID>
  </reference>
  <reference>
    <citation>Greenfield SP, Chesney RW, Carpenter M, Moxey-Mims M, Nyberg L, Hoberman A, Keren R, Matthews R, Mattoo T. Vesicoureteral reflux: the RIVUR study and the way forward. J Urol. 2008 Feb;179(2):405-7.</citation>
    <PMID>18076937</PMID>
  </reference>
  <reference>
    <citation>Chesney RW, Carpenter MA, Moxey-Mims M, Nyberg L, Greenfield SP, Hoberman A, Keren R, Matthews R, Matoo TK; members of the RIVUR Steering Committee. Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR): background commentary of RIVUR investigators. Pediatrics. 2008 Dec;122 Suppl 5:S233-9. doi: 10.1542/peds.2008-1285c.</citation>
    <PMID>19018047</PMID>
  </reference>
  <reference>
    <citation>Keren R. Pediatrics. RIVUR trial. Introduction. Pediatrics. 2008 Dec;122 Suppl 5:S231-2.</citation>
    <PMID>19086141</PMID>
  </reference>
  <reference>
    <citation>Greenfield SP, Carpenter MA, Chesney RW, Zerin JM, Chow J. The RIVUR voiding cystourethrogram pilot study: experience with radiologic reading concordance. J Urol. 2012 Oct;188(4 Suppl):1608-12. doi: 10.1016/j.juro.2012.06.032. Epub 2012 Aug 19.</citation>
    <PMID>22910235</PMID>
  </reference>
  <reference>
    <citation>Hoberman A, Shaikh N, Bhatnagar S, Haralam MA, Kearney DH, Colborn DK, Kienholz ML, Wang L, Bunker CH, Keren R, Carpenter MA, Greenfield SP, Pohl HG, Mathews R, Moxey-Mims M, Chesney RW. Factors that influence parental decisions to participate in clinical research: consenters vs nonconsenters. JAMA Pediatr. 2013 Jun;167(6):561-6. doi: 10.1001/jamapediatrics.2013.1050.</citation>
    <PMID>23546617</PMID>
  </reference>
  <reference>
    <citation>Bhatnagar S, Hoberman A, Kearney DH, Shaikh N, Moxey-Mims MM, Chesney RW, Carpenter MA, Greenfield SP, Keren R, Mattoo TK, Mathews R, Gravens-Mueller L, Ivanova A. Development and impact of an intervention to boost recruitment in a multicenter pediatric randomized clinical trial. Clin Pediatr (Phila). 2014 Feb;53(2):151-7. doi: 10.1177/0009922813506961. Epub 2013 Oct 22.</citation>
    <PMID>24151147</PMID>
  </reference>
  <reference>
    <citation>Chesney RW, Patters AB. Childhood vesicoureteral reflux studies: registries and repositories sources and nosology. J Pediatr Urol. 2013 Dec;9(6 Pt A):731-7. doi: 10.1016/j.jpurol.2012.09.003. Epub 2012 Oct 5. Review.</citation>
    <PMID>23044377</PMID>
  </reference>
  <results_reference>
    <citation>Carpenter MA, Hoberman A, Mattoo TK, Mathews R, Keren R, Chesney RW, Moxey-Mims M, Greenfield SP; RIVUR Trial Investigators. The RIVUR trial: profile and baseline clinical associations of children with vesicoureteral reflux. Pediatrics. 2013 Jul;132(1):e34-45. doi: 10.1542/peds.2012-2301. Epub 2013 Jun 10.</citation>
    <PMID>23753091</PMID>
  </results_reference>
  <results_reference>
    <citation>RIVUR Trial Investigators, Hoberman A, Greenfield SP, Mattoo TK, Keren R, Mathews R, Pohl HG, Kropp BP, Skoog SJ, Nelson CP, Moxey-Mims M, Chesney RW, Carpenter MA. Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med. 2014 Jun 19;370(25):2367-76. doi: 10.1056/NEJMoa1401811. Epub 2014 May 4.</citation>
    <PMID>24795142</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2006</study_first_submitted>
  <study_first_submitted_qc>November 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2006</study_first_posted>
  <results_first_submitted>December 4, 2014</results_first_submitted>
  <results_first_submitted_qc>April 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 16, 2015</results_first_posted>
  <last_update_submitted>April 15, 2015</last_update_submitted>
  <last_update_submitted_qc>April 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vesicoureteral Reflux</keyword>
  <keyword>Urinary Tract Infections</keyword>
  <keyword>Renal Scarring</keyword>
  <keyword>Antibiotic Resistance</keyword>
  <keyword>Controlled Clinical Trial</keyword>
  <keyword>Trimethoprim-Sulfamethoxazole</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Vesico-Ureteral Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Trimethoprim-Sulfamethoxazole</title>
          <description>Trimethoprim-Sulfamethoxazole: Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Cherry flavored liquid suspension matched to active comparator.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="302"/>
                <participants group_id="P2" count="305"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Outcome Renal Scan</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="235"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Assessments for New Scarring</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Outcome Stool Assessed</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Recurrent UTI With E. Coli</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Recurrent UTI With TMP-SMZ Panel</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="261"/>
                <participants group_id="P2" count="259"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Trimethoprim-Sulfamethoxazole</title>
          <description>Trimethoprim-Sulfamethoxazole: Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Cherry flavored liquid suspension matched to active comparator.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="302"/>
            <count group_id="B2" value="305"/>
            <count group_id="B3" value="607"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" lower_limit="5" upper_limit="31"/>
                    <measurement group_id="B2" value="12" lower_limit="6" upper_limit="30"/>
                    <measurement group_id="B3" value="12" lower_limit="6" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="277"/>
                    <measurement group_id="B2" value="281"/>
                    <measurement group_id="B3" value="558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="302"/>
                    <measurement group_id="B2" value="305"/>
                    <measurement group_id="B3" value="607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recurrent Febrile or Symptomatic Urinary Tract Infection During 2-year Follow-up</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trimethoprim-Sulfamethoxazole</title>
            <description>Trimethoprim-Sulfamethoxazole: Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Cherry flavored liquid suspension matched to active comparator.</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrent Febrile or Symptomatic Urinary Tract Infection During 2-year Follow-up</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outcome Renal Scarring</title>
        <description>Renal scarring was defined as a decreased uptake of tracer that was associated with loss of contours or the presence of cortical thinning. Outcome dimercaptosuccinic acid (DMSA) scan was performed at 2 years after enrollment or 3-4 months after the child had met treatment failure criteria.</description>
        <time_frame>2 years</time_frame>
        <population>The analysis population excluded 75 subjects in the trimethoprim-sulfamethoxazole group and 70 subjects in the placebo group who did not have an outcome dimercaptosuccinic acid scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Trimethoprim-Sulfamethoxazole</title>
            <description>Trimethoprim-Sulfamethoxazole: Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Cherry flavored liquid suspension matched to active comparator.</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome Renal Scarring</title>
          <description>Renal scarring was defined as a decreased uptake of tracer that was associated with loss of contours or the presence of cortical thinning. Outcome dimercaptosuccinic acid (DMSA) scan was performed at 2 years after enrollment or 3-4 months after the child had met treatment failure criteria.</description>
          <population>The analysis population excluded 75 subjects in the trimethoprim-sulfamethoxazole group and 70 subjects in the placebo group who did not have an outcome dimercaptosuccinic acid scan.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Renal Scarring on Outcome Scan</title>
        <description>Severe renal scarring was defined as scarring in more than 4 of 12 segments in at least one kidney or global atrophy characterized by diffusely scarred and shrunken kidney. Outcome DMSA scan performed at 2 years after enrollment or 3-4 months after the child had met treatment failure criteria.</description>
        <time_frame>2 years</time_frame>
        <population>The analysis population excluded 75 subjects in the trimethoprim-sulfamethoxazole group and 70 subjects in the placebo group who did not have an outcome dimercaptosuccinic acid scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Trimethoprim-Sulfamethoxazole</title>
            <description>Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Cherry flavored liquid suspension matched to active comparator.</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Renal Scarring on Outcome Scan</title>
          <description>Severe renal scarring was defined as scarring in more than 4 of 12 segments in at least one kidney or global atrophy characterized by diffusely scarred and shrunken kidney. Outcome DMSA scan performed at 2 years after enrollment or 3-4 months after the child had met treatment failure criteria.</description>
          <population>The analysis population excluded 75 subjects in the trimethoprim-sulfamethoxazole group and 70 subjects in the placebo group who did not have an outcome dimercaptosuccinic acid scan.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Renal Scarring on Outcome Scan</title>
        <description>New renal scarring was defined as scarring on the outcome renal scan with technetium -99m-labeled dimercaptosuccinic acid that was not present at baseline. Outcome DMSA scan performed at 2 years after enrollment or 3-4 months after the child had met treatment failure criteria.</description>
        <time_frame>2 years</time_frame>
        <population>The analysis population excluded 82 subjects in the trimethoprim-sulfamethoxazole group and 78 subjects in the placebo group who did not have an outcome dimercaptosuccinic acid scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Trimethoprim-Sulfamethoxazole</title>
            <description>Trimethoprim-Sulfamethoxazole: Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Cherry flavored liquid suspension matched to active comparator.</description>
          </group>
        </group_list>
        <measure>
          <title>New Renal Scarring on Outcome Scan</title>
          <description>New renal scarring was defined as scarring on the outcome renal scan with technetium -99m-labeled dimercaptosuccinic acid that was not present at baseline. Outcome DMSA scan performed at 2 years after enrollment or 3-4 months after the child had met treatment failure criteria.</description>
          <population>The analysis population excluded 82 subjects in the trimethoprim-sulfamethoxazole group and 78 subjects in the placebo group who did not have an outcome dimercaptosuccinic acid scan.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.94</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Failure Composite</title>
        <description>Treatment failure was defined as the occurrence of two febrile urinary tract infections (UTIs), one febrile UTI and three symptomatic UTIs, four symptomatic UTIs, or new or worsening renal scarring on an interim scan (e.g,, the 12-month visit); renal scans from the 2-year visit are NOT considered in the treatment failure criteria.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trimethoprim-Sulfamethoxazole</title>
            <description>Trimethoprim-Sulfamethoxazole: Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Cherry flavored liquid suspension matched to active comparator.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failure Composite</title>
          <description>Treatment failure was defined as the occurrence of two febrile urinary tract infections (UTIs), one febrile UTI and three symptomatic UTIs, four symptomatic UTIs, or new or worsening renal scarring on an interim scan (e.g,, the 12-month visit); renal scans from the 2-year visit are NOT considered in the treatment failure criteria.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of E.Coli Resistant to Trimethoprim-Sulfamethoxazole (TMP-SMZ) (Based on Rectal Swab)</title>
        <time_frame>2 years</time_frame>
        <population>The analysis population excluded 99 subjects in the trimethoprim-sulfamethoxazole group and 95 subjects in the placebo group who did not have stool analyzed at the outcome visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Trimethoprim-Sulfamethoxazole</title>
            <description>Trimethoprim-Sulfamethoxazole: Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Cherry flavored liquid suspension matched to active comparator.</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of E.Coli Resistant to Trimethoprim-Sulfamethoxazole (TMP-SMZ) (Based on Rectal Swab)</title>
          <population>The analysis population excluded 99 subjects in the trimethoprim-sulfamethoxazole group and 95 subjects in the placebo group who did not have stool analyzed at the outcome visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.065</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent Febrile or Symptomatic UTI With Resistant E. Coli</title>
        <time_frame>2 years</time_frame>
        <population>The analysis population is restricted to the 30 subjects in the trimethoprim-sulfamethoxazole (TMP-SMZ) group and 57 subjects in the placebo group who had a recurrent UTI with E. coli for which sensitivity to TMP-SMZ was assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Trimethoprim-Sulfamethoxazole</title>
            <description>Trimethoprim-Sulfamethoxazole: Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Cherry flavored liquid suspension matched to active comparator.</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrent Febrile or Symptomatic UTI With Resistant E. Coli</title>
          <population>The analysis population is restricted to the 30 subjects in the trimethoprim-sulfamethoxazole (TMP-SMZ) group and 57 subjects in the placebo group who had a recurrent UTI with E. coli for which sensitivity to TMP-SMZ was assessed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent Febrile or Symptomatic UTI With Any Resistant Pathogen</title>
        <time_frame>2 years</time_frame>
        <population>The analysis population is restricted to the 38 subjects in the trimethoprim-sulfamethoxazole (TMP-SMZ) group and 69 subjects in the placebo group who had a recurrent UTI with an organism for which sensitivity to TMP-SMZ was assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Trimethoprim-Sulfamethoxazole</title>
            <description>Trimethoprim-Sulfamethoxazole: Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Cherry flavored liquid suspension matched to active comparator.</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrent Febrile or Symptomatic UTI With Any Resistant Pathogen</title>
          <population>The analysis population is restricted to the 38 subjects in the trimethoprim-sulfamethoxazole (TMP-SMZ) group and 69 subjects in the placebo group who had a recurrent UTI with an organism for which sensitivity to TMP-SMZ was assessed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Trimethoprim-Sulfamethoxazole</title>
          <description>Trimethoprim-Sulfamethoxazole: Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Cherry flavored liquid suspension matched to active comparator.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="58" subjects_affected="43" subjects_at_risk="302"/>
                <counts group_id="E2" events="80" subjects_affected="55" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="302"/>
                <counts group_id="E2" events="33" subjects_affected="24" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="302"/>
                <counts group_id="E2" events="20" subjects_affected="14" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="30" subjects_affected="23" subjects_at_risk="302"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="302"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="302"/>
                <counts group_id="E2" events="27" subjects_affected="19" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Results may not apply to children with different demographic or clinical characteristics or in locales where choice of TMP-SMZ may be limited by susceptibility patterns or clinical acceptability. Some subgroup analyses had limited statistical power.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Myra Carpenter, Senior Investigator</name_or_title>
      <organization>UNC Chapel Hill</organization>
      <phone>919-962-3245</phone>
      <email>myra_carpenter@unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

